Aveanna Healthcare Holdings Inc. AVAH R2KR3KPHARMA
Company Overview
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Why Investors Should Care
Return on capital employed stands at 16.2%.
Trades at a P/E of 10.6, below the sector median of 25.6.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $2.43B (+0.0% YoY); net profit $225.03M.
- Trailing 12 Months Year-on-year growth — revenue +13.7%, earnings +38.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.39% |
| 1 Year: | 13.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 38.50% |
Stock Price Performance
| 1 Year: | +86.29% |
| 6 Months: | +104.61% |
| 3 Months: | +40.95% |
| 1 Month: | +4.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.59 · Neutral
P/E of 10.57 is below the sector median of 25.61 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVAH Aveanna Healthcare Holdings Inc. R2KR3KPHARMA | 13.32 | 10.57 | $2.91B | 0.00% | 16.15% | - | 8.39% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 355.22M | 351.58M | 366.00M | 417.16M | 436.11M | 411.28M | 450.53M | 442.95M | 443.01M | 466.41M | 471.94M | 478.01M | 490.65M | 504.96M | - | - | 559.22M | 589.55M | 621.94M | 662.48M | 647.91M | 647.91M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.67M | 378.75M | 419.12M | 449.18M | 442.49M | - |
| Gross Profit | 107.54M | 106.63M | 114.13M | 131.68M | 146.59M | 139.74M | 144.83M | 145.04M | 134.58M | 144.47M | 155.25M | 147.26M | 145.85M | 158.27M | - | - | 183.56M | 210.80M | 202.82M | 213.30M | 205.43M | 205.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 131.65M | 127.37M | 150.42M | 140.77M | 132.99M | - |
| Operating Income | 17.87M | -51.96M | 12.88M | 28.30M | 30.29M | 18.35M | 13.78M | -456.38M | 4.79M | 17.64M | 37.49M | -76.35M | 22.87M | 37.13M | - | - | 51.91M | 83.43M | 52.41M | 72.53M | 72.44M | 69.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51.78M | 87.11M | 55.67M | 78.04M | 80.82M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.69M | 36.00M | 35.13M | 31.61M | 28.19M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.15M | 44.14M | 13.42M | 39.24M | 44.98M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.96M | 17.11M | -647.00K | -139.51M | 3.32M | - |
| Net Income | 37.64M | -77.55M | -7.40M | 5.80M | 1.26M | 2.09M | 25.33M | -473.89M | 24.30M | -32.00M | 25.60M | -102.39M | -11.17M | 13.91M | - | - | 5.19M | 27.02M | 14.06M | 178.75M | 41.65M | 41.65M |
| Diluted EPS | 0.27 | -0.55 | -0.05 | 0.04 | 0.01 | 0.01 | 0.14 | -2.56 | 0.13 | -0.17 | 0.13 | -0.54 | -0.06 | 0.07 | - | - | 0.03 | 0.13 | 0.06 | 0.80 | 0.19 | 0.19 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.38B | 1.50B | - | 1.68B | 1.79B | 1.90B | 2.02B | 2.43B | 2.43B |
| Cost of Revenue | - | - | - | - | 1.23B | 1.30B | 1.39B | 1.62B | - |
| Gross Profit | 419.25M | 454.51M | - | 542.40M | 553.23M | 595.43M | 635.54M | 810.48M | 810.48M |
| Operating Expenses | - | - | - | - | 520.06M | 481.76M | 494.26M | 550.21M | - |
| Operating Income | 38.95M | -3.49M | - | -36.11M | 33.17M | 113.67M | 141.28M | 260.28M | 256.46M |
| EBITDA | - | - | - | - | -525.06M | 39.17M | 187.38M | 269.40M | - |
| Interest Expense | - | - | - | - | 99.94M | 148.07M | 151.14M | 134.23M | - |
| Pretax Income | - | - | - | - | -663.81M | -139.00M | 5.07M | 106.95M | - |
| Tax Provision | - | - | - | - | -1.78M | -4.47M | 16.00M | -118.09M | - |
| Net Income | -76.52M | -57.05M | - | -117.04M | -662.03M | -134.52M | -10.93M | 225.03M | 225.03M |
| Diluted EPS | - | - | - | -0.69 | -3.57 | -0.71 | -0.06 | 1.05 | 1.05 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.84B | - | 2.33B | 1.71B | 1.61B | 1.66B | 2.01B | 2.01B |
| Current Assets | - | - | - | - | - | 269.75M | 314.89M | 392.67M | 560.23M | - |
| Cash & Equivalents | - | - | 137.34M | - | 30.49M | 19.22M | 43.94M | 84.29M | 193.26M | 193.26M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 225.63M | 245.81M | 277.66M | 316.12M | - |
| Total Liabilities | - | - | 1.58B | - | 1.70B | 1.72B | 1.74B | 1.79B | 1.82B | 1.82B |
| Current Liabilities | - | - | 260.41M | - | 344.83M | 326.50M | 354.76M | 402.17M | 424.46M | 424.46M |
| Long Term Debt | - | - | 1.16B | - | 1.23B | 1.28B | 1.28B | 1.27B | 1.29B | 1.29B |
| Total Debt | - | - | - | - | - | 1.50B | 1.50B | 1.50B | 1.51B | - |
| Total Equity | 344.99M | 270.19M | 265.03M | - | 635.82M | -4.17M | -127.44M | -122.09M | 195.19M | 194.46M |
| Shares Outstanding | - | - | - | - | - | 188.86M | 190.73M | 193.23M | 211.00M | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.71M | 116.62M | - | -11.35M | -48.40M | 22.67M | 32.64M | 125.86M | 125.86M |
| Investing Cash Flow | -17.82M | -193.54M | - | -681.83M | -25.29M | -8.79M | -6.32M | -22.30M | -22.30M |
| Financing Cash Flow | 21.86M | 210.94M | - | 586.33M | 62.42M | 10.85M | 14.03M | 5.41M | 5.41M |
| Capital Expenditure | -16.64M | -15.24M | - | -15.95M | -12.01M | -8.79M | -6.32M | -7.45M | - |
| Free Cash Flow | -25.35M | 101.38M | - | -27.30M | -60.41M | 13.88M | 26.32M | 118.41M | - |
| Net Change in Cash | - | - | - | - | -11.27M | 24.73M | 40.35M | 108.97M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 30.3% | 30.4% | - | 32.3% | 30.9% | 31.4% | 31.4% | 33.3% | 33.3% |
| Operating Margin % | 2.8% | -0.2% | - | -2.2% | 1.9% | 6.0% | 7.0% | 10.7% | 10.5% |
| Net Margin % | -5.5% | -3.8% | - | -7.0% | -37.0% | -7.1% | -0.5% | 9.2% | 9.2% |
| ROE % | -28.3% | -21.5% | - | -18.4% | 15,857.1% | 105.6% | 9.0% | 115.3% | 115.7% |
| ROCE % | - | -0.2% | - | -1.8% | 2.4% | 9.0% | 11.2% | 16.4% | 16.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Investors Llc | 37.39% | 81.60M | $999.61M |
| 2 | J.H. Whitney Equity Partners VII, LLC | 12.40% | 27.06M | $331.51M |
| 3 | Nut Tree Capital Management, LP | 5.92% | 12.92M | $158.30M |
| 4 | Blackrock Inc. | 3.40% | 7.41M | $90.77M |
| 5 | Ophir Asset Management Pty Ltd | 2.34% | 5.10M | $62.48M |
| 6 | Vanguard Capital Management LLC | 1.68% | 3.67M | $45.00M |
| 7 | Braidwell LP | 1.40% | 3.07M | $37.55M |
| 8 | Boston Partners | 1.32% | 2.87M | $35.17M |
| 9 | Citadel Advisors Llc | 1.05% | 2.29M | $28.00M |
| 10 | Dimensional Fund Advisors LP | 1.03% | 2.26M | $27.66M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVAH
AVAH Nov 2026 12.500 put (AVAH261120P00012500) Interactive Stock Chart - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5WMFA1YjBjSFhmVjVxd0IwUlEtNl9MYjNwWm0zVTczM0NJWi1WYjlKZDNJd3BFVWVJZEFiT0dfa2t1eko0U2FqQzVEZ1FUVWs2ZjVsMEdCXzEwUERfSXVtcXN2X0VvMmhjVDRKa21B?oc=5" target="_blank">AVAH Nov 2026 12.50…
Is Aveanna Healthcare Holdings (AVAH) Still Below Fair Value Following Its Zacks Upgrade? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNN0RHZHBhQ0dWckdFOS0xMmNmbzJyZENvaGk5ZHpTRWdTdncwdDZkS1Q3TDNVUUY1NTlLQTBhaEpUUkN4T3Ywb1J2QkhyUC05ZGdpbFM3MWE0N09pY3AzdmoyZXBWbFFFSXZVQTlvS3ZHRnJtbllsT1dWQ2c1cTN0OVpwZWtqaXZiZlUtZn…
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQOHlXX3VzYVRGOHd6a3Rab0xUQUJWaTJHcEhQSGlPOEdPaEt6MGdRb2Q4OFJxM193dkRyTlpGa21YbE1PQjlrcGcyejg4RWQ4Qmt4d21hT1ItMC1TRndZRHljNjBHOTJIY09TcGZBMlNJTWlYOUVlMGpQd0VRamxsLWRCN21TV0MyVjcwTX…
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMzVyTXhzZHVPNVNYbWdORVJzM3E0WHZJNEtPbm1vcnBVcFVJNzVZZnBNM2k2SmVWTEZkWlhfWVllUzM2bWVreEo5Y2xHN0N5SVdLa3BCdVJQc2VnNXlGZXNLaGNncDE0WDVQNWVqMUQxLTJJc0NGRHR3em5rdE5TM0lJZXp1WGItaTU0d1…
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNLWlJSjRHTjV1MWlacG1Mdkx0Zl9oYjk1UlFYbjRuUWcwVm1VemVNWEpua2l6RnYyQ2dVSnJzUTJpUkYyWnR0ZjgyLXloaVA2U05QZmJCaTNTTW1YUVBHSmJlbTNVenNjTVVHTk55eFU3dFJUV2VYbzB3WkhyN21kM3FtdnpUeHJnVTg4c2…
AVAH261120P00012500 Interactive Stock Chart | AVAH Nov 2026 12.500 put Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE13dWhBNWhrYVl2S3JmazB2M1FqQmNJc1FXU2lxZG1Xa2hhTXVYdHZEV1NHbFlJX0F6Zmw5b3hpbEpGbmVVcTlET0d1WUZScVEzd0ozbkRHeHVxVGJENG5lLQ?oc=5" target="_blank">AVAH261120P00012500 Interactive Stock…
AVAH — Frequently Asked Questions
What is the current share price of Aveanna Healthcare Holdings Inc. (AVAH)?
As of 2026-10-22 16:30 PDT, Aveanna Healthcare Holdings Inc. (AVAH) trades at $13.32 on NasdaqGS. Its 52-week range is $6.22 to $14.38.
What is the market capitalisation of AVAH?
Aveanna Healthcare Holdings Inc. (AVAH) has a market capitalisation of $2.91B on NasdaqGS.
What is the P/E ratio of AVAH?
AVAH trades at a trailing price-to-earnings (P/E) ratio of 10.57. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 9.28.
Is AVAH a good stock to buy?
This page provides a data-driven analysis of Aveanna Healthcare Holdings Inc. (AVAH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.